Health Care

UnitedHealth Group lifts 2026 earnings outlook to $20.50 EPS, cuts costs, and reshapes Medicare plans—find out how its strategic moves could boost investor returns.

Explore how Stryker’s $400 M stake in CMR Surgical and exclusive U.S. sales of the Versius robot could reshape robotic‑assisted surgery and drive future growth.

Explore Cigna Group’s Q3 2026 earnings, market stance, and digital health strategy—why investors keep a close eye on this global insurer’s steady growth.

Argenx shares dip after stopping Sjögren’s trial, but upbeat FB102 celiac results and a growing pipeline keep investors optimistic about future growth.

Danaher’s new AI‑powered autonomous lab could slash drug‑discovery times 8×, driving faster, scalable reagent production and higher returns for investors in life sciences.

Genmab’s Rina‑S and EPCORE DLBCL‑2 trials show 45.9% ovarian cancer responses and 51% DLBCL risk reduction, boosting investor confidence and revenue outlook.

Quest Diagnostics’ 2026 stock outlook shows strong YTD gains, AI‑powered lab tech, and a validated liquid‑biopsy test that could boost precision oncology revenue.

Regeneron boosts growth with an $8bn Sanofi tie‑up and breakthrough ovarian‑cancer and obesity trials, sparking fresh investor interest.

GSK shares dip on weaker UK PMI, yet a robust drug pipeline and diversified portfolio keep long‑term prospects bright for investors.

Explore Eli Lilly’s $6.5 B Houston API plant and growing obesity‑drug pipeline—discover how the pharma giant’s strategy, market position, and patent risks shape its 2026 outlook.